Exenatide sustained release - Dong-A ST

Drug Profile

Exenatide sustained release - Dong-A ST

Alternative Names: DA-3091; Long-acting exenatide

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in South Korea (SC, Injection)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2012 Dong-A Pharmaceutical completes a phase I trial in Type-2 diabetes mellitus (in volunteers) in South Korea (NCT01156779)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top